I'm LongbridgeAI, I can summarize articles.Goldman Sachs issued a research report saying that CSPC PHARMA (01093.HK) +0.230 (+2.880%) Short selling $200.72M; Ratio 40.930% 's 3Q finished drug sales beat expectations, driven by momentum in the central nervous system (CNS) business and operating leverage, while profit also exceeded expectations. Management maintained an unchanged tone on the growth outlook.
The broker noted that CSPC PHARMA's 3Q revenue was RMB6.7 billion, up 0.7% YoY and broadly in line with expectations. Profit reached RMB982 million, up 1.9% YoY. Excluding licensing income, profit was about RMB665 million, representing an estimated YoY increase of about 17%. The finished drug business remained solid, rising 10% YoY, above the broker's previous forecast of 6% growth. Among them, the CNS business was particularly strong, surging 32% YoY, driven by retail sales of NBP and Mingfule. The oncology portfolio remained under pressure, falling 23% YoY, while APIs were weaker, declining 23.8% YoY and 16.6% QoQ. Gross margin remained stable QoQ, while selling expenses fell another 6.9% YoY.
The broker said that despite solid momentum in finished drugs during 2Q and 3Q, management remained relatively conservative on the growth outlook, only guiding for positive growth by 2027. Management expects NBP to continue benefiting from expansion in self-paid retail channels and longer treatment courses, while unchanged pricing in this year's National Reimbursement Drug List renewal was a positive surprise. Following an approximately 9.4% price cut in the National Reimbursement Drug List, Mingfule should pursue volume expansion. More importantly, management expects new products to become more meaningful growth drivers in 2027, including new albumin-bound paclitaxel, GLP-1 products and SYS6010 (EGFR ADC). Together with continued growth in the CNS business, these are expected to support guidance for positive finished drug sales growth in 2027 and potentially drive the oncology business back to positive growth in 2026 after continued pressure from centralized procurement and legacy products.
Goldman Sachs adjusted its earnings forecasts for CSPC PHARMA for 2026, 2027 and 2028, lowering them by 2.1% and 0.1%, and raising them by 0.2%, respectively, mainly reflecting lower-than-expected collaboration income in 3Q, while also raising its 2026 finished drug sales growth assumption from 9% to 10%. Based on updated forecasts and a DCF roll-forward, the broker lifted its 12-month TP from HKD12.56 to HKD12.83 and maintained a Buy rating. (da/j)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-19 12:25.)
